PMV Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David H. Mack
- Full Time Employees
- 54
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400 Alexander Park Drive Princeton NJ United States of America 08540
- IPO Date
- Sep 25, 2020
- CIK
- 0001699382
- Website
- pmvpharma.com
- Similar Companies
- Business
- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) is a precision oncology company that pioneers the discovery and development of small-molecule, tumor-agnostic therapies targeting p53 mutations prevalent in approximately half of all human cancers. Founded in 2013 and headquartered in Princeton, New Jersey, the company focuses on restoring the tumor-suppressing function of mutated p53 proteins through structural correction, with operations centered in the United States and global clinical trial sites across the U.S., Europe, U.K., and Asia-Pacific. Its lead product candidate, rezatapopt (PC14586), is an orally available, first-in-class selective p53 Y220C reactivator in Phase 2 pivotal development under the PYNNACLE trial (NCT04585750) for advanced solid tumors harboring the TP53 Y220C mutation and KRAS wild-type status, including cohorts for ovarian, lung, breast, endometrial cancers, and other solid tumors; the U.S. FDA has granted Fast Track designation to rezatapopt for locally advanced or metastatic solid tumors with p53 Y220C. The pipeline also includes an investigator-initiated Phase 1b study of rezatapopt monotherapy and in combination with azacitidine for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with p53 Y220C, conducted in collaboration with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center; plus undisclosed early-stage programs targeting other p53 hotspot mutations and solid tumors. Recent advancements include over 90% site activation for the Phase 2 PYNNACLE monotherapy trial with interim data expected mid-2025; promising Phase 1 PYNNACLE results showing confirmed partial responses in 7 of 15 ovarian cancer patients (median duration seven months) and 3 of 8 breast cancer patients; discontinuation of the rezatapopt plus KEYTRUDA (pembrolizumab) combination arm due to insufficient clinical benefit; a partnership with Foundation Medicine for companion diagnostic development of FoundationOne CDx to identify p53 Y220C patients; enrollment commencement in the MD Anderson Phase 1b AML/MDS study; presentation of ovarian and breast cancer data at the 2024 Society for Gynecologic Oncology and San Antonio Breast Cancer Symposiums, respectively; and publication of rezatapopt discovery in ACS Medicinal Chemistry Letters, with the company reporting a $183.3 million cash position as of December 31, 2024, supporting operations through 2026 alongside a reduced net loss of $58.7 million for the year.
Company News
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to Analysts
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PMV Pharma Announces Proposed Public Offering of Securities
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PMV Pharmaceuticals Announces Board Chair Transition
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Comparison
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals (PMVP) Q2 Loss Jumps
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences